ALGN vs. CYTK: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ALGN and CYTK, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
ALGN dominates in value with a market cap of 12.46 billion USD, eclipsing CYTK’s 3.69 billion USD by roughly 3.38×.
ALGN’s beta of 1.68 points to much larger expected swings compared to CYTK’s calmer 0.81, suggesting both higher upside and downside potential.
| Symbol | ALGN | CYTK |
|---|---|---|
| Company Name | Align Technology, Inc. | Cytokinetics, Incorporated |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Medical - Devices | Biotechnology |
| CEO | Mr. Joseph M. Hogan | Mr. Robert I. Blum |
| Price | 171.91 USD | 30.873 USD |
| Market Cap | 12.46 billion USD | 3.69 billion USD |
| Beta | 1.68 | 0.81 |
| Exchange | NASDAQ | NASDAQ |
| IPO Date | January 30, 2001 | April 30, 2004 |
| ADR | No | No |
Performance Comparison
This chart compares the performance of ALGN and CYTK over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
The section examines key financial ratios to assess the valuation of ALGN and CYTK based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.
- CYTK shows a negative P/E of -5.95, highlighting a year of losses, whereas ALGN at 30.88 trades on solid profitability.
- CYTK carries a sub-zero price-to-book ratio of -13.73, indicating negative equity. In contrast, ALGN (P/B 3.33) has positive book value.
- CYTK reports a negative Price-to-Free Cash Flow ratio of -9.01, showing a cash flow shortfall that could threaten its operational sustainability, while ALGN at 19.76 maintains positive cash flow.
| Symbol | ALGN | CYTK |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 30.88 | -5.95 |
| Forward PEG Ratio (TTM) | 2.92 | 10.43 |
| Price-to-Sales Ratio (P/S, TTM) | 3.13 | 191.86 |
| Price-to-Book Ratio (P/B, TTM) | 3.33 | -13.73 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 19.76 | -9.01 |
| EV-to-EBITDA (TTM) | 14.56 | -8.54 |
| EV-to-Sales (TTM) | 2.94 | 229.18 |
| EV-to-Free Cash Flow (TTM) | 18.56 | -10.76 |
Dividend Comparison
Neither ALGN nor CYTK currently pays a dividend yield; this often indicates they are reinvesting earnings for growth, prioritizing long-term expansion over immediate cash returns to shareholders.
| Symbol | ALGN | CYTK |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of ALGN and CYTK, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- CYTK has negative equity (debt-to-equity ratio -2.97), suggesting asset shortfalls, whereas ALGN at 0.03 preserves healthier equity coverage.
- ALGN shows “--” (minimal interest expense), but CYTK is in the red with interest coverage -6.14, signaling a net operating loss.
| Symbol | ALGN | CYTK |
|---|---|---|
| Current Ratio (TTM) | 1.21 | 5.99 |
| Quick Ratio (TTM) | 1.08 | 5.99 |
| Debt-to-Equity Ratio (TTM) | 0.03 | -2.97 |
| Debt-to-Assets Ratio (TTM) | 0.02 | 0.63 |
| Interest Coverage Ratio (TTM) | -- | -6.14 |